Canaccord Raises Target Price for STAAR Surgical Following Strong Sales Performance

Canaccord Genuity analysts have raised the target price for STAAR Surgical's stock following the company's first-quarter sales figures exceeding expectations. The firm's strong performance in intraocular lens technology, particularly growth in international markets, was cited as the primary reason for this upgrade. Analysts noted that the company's ICL (Implantable Collamer Lens) product family is benefiting from rising global demand, which is positively impacting financial results. Operational efficiency and market share gains were also highlighted as other favorable factors. The report stated that, despite the current macroeconomic environment, demand for refractive surgery has shown resilience, and STAAR Surgical continues to capitalize on this trend. This strengthens growth expectations for the company in upcoming quarters. Canaccord revised its previous target price for the stock to a higher level. This revision reflects confidence in the company's roadmap for sustainable growth and profitability. Investors continue to monitor the company's upcoming official financial disclosures and developments in market conditions. This is not investment advice.